The stock of Gracell Biotechnologies Inc. (NASDAQ:GRCL) last traded at $2.14, down -1.83% from the previous session.
Data from the available sources indicates that Gracell Biotechnologies Inc. (NASDAQ:GRCL) is covered by 7 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $21.00 and a low of $7.00, we find $12.00. Given the previous closing price of $2.18, this indicates a potential upside of 450.46 percent. GRCL stock price is now -21.79% away from the 50-day moving average and -30.64% away from the 200-day moving average. The market capitalization of the company currently stands at $141.54M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
In total, 0 analysts have assigned it a hold rating, and 7 have given it a buy rating. Brokers who have rated the stock have averaged $14.29 as their price target over the next twelve months.
With the price target of $6, H.C. Wainwright recently initiated with Buy rating for Gracell Biotechnologies Inc. (NASDAQ: GRCL). On September 22, 2022, Citigroup recently initiated its ‘Buy’ rating on the stock quoting a target price of $12, while ‘Wells Fargo’ rates the stock as ‘Overweight’.
A total of 7.89% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GRCL stock. A new stake in Gracell Biotechnologies Inc. shares was purchased by GREAT POINT PARTNERS I LP during the first quarter worth $961,000. BALYASNY ASSET MANAGEMENT LLC invested $53,000 in shares of GRCL during the first quarter. In the first quarter, UBS GROUP AG acquired a new stake in Gracell Biotechnologies Inc. valued at approximately $8,000. CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. acquired a new stake in GRCL for approximately $1,000. In total, there are 49 active investors with 45.50% ownership of the company’s stock.
With an opening price of $2.1200 on Tuesday morning, Gracell Biotechnologies Inc. (NASDAQ: GRCL) set off the trading day. During the past 12 months, Gracell Biotechnologies Inc. has had a low of $1.68 and a high of $5.69. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 6.80, and a quick ratio of 6.80. The fifty day moving average price for GRCL is $2.7362 and a two-hundred day moving average price translates $3.0854 for the stock.
The latest earnings results from Gracell Biotechnologies Inc. (NASDAQ: GRCL) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.3, missing analysts’ expectations of -$0.07 by -0.23. This compares to -$0.30 EPS in the same period last year. For the current quarter, analysts expect GRCL to generate $20k in revenue.
Gracell Biotechnologies Inc.(GRCL) Company Profile
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People’s Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin’s lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company’s product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.
